Dr. Borghaei Discusses the Results of CheckMate-227 in NSCLC

Video

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the CheckMate-227 trial in non–small cell lung cancer.

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the CheckMate-227 trial in non—small cell lung cancer (NSCLC).

CheckMate-227 is a phase III study of nivolumab (Opdivo) plus platinum-doublet chemotherapy versus chemotherapy as a first-line treatment for patients with advanced NSCLC who have <1% PD-L1 tumor expression. Results showed that the addition of nivolumab to chemotherapy did improve progression-free survival in this population, but the responses were not durable. Borghaei says that durability of response is something that has been seen in other immunotherapy-based studies, and is a factor that investigators believe is important in determining the activity of the drug.

Tumor mutational burden (TMB) is a biomarker that has been studied in patients with NSCLC. Particularly, patients with high TMB have demonstrated a greater benefit with nivolumab plus ipilimumab (Yervoy), as well as nivolumab plus chemotherapy. Borghaei says that TMB may be a good way to select patients with NSCLC for treatment with immunotherapy agents.

Related Videos
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD